An innovative microscope slide – NanoMslide – is promising to revolutionise medical imaging after researchers demonstrated that it could be used to detect breast cancer cells in patients.
The technology was developed at La Trobe University by Professor Brian Abbey and co-inventor Dr Eugeniu Balaur, who then teamed up with Associate Professor Belinda Parker’s group at the Peter MacCallum Cancer Centre to trial it as an aid to diagnosing very early-stage breast cancer.
In their study published today in Nature, they demonstrate that by modifying the surface of conventional microscope slides at the nanoscale, biological structures and cells take on a striking colour contrast which can be used to instantly detect disease.
“Current approaches to tissue imaging often rely on staining or labelling cells in order to render them visible under the microscope,” Professor Abbey said.
“Even with staining or labelling, it can be challenging for pathologists to detect cancer cells, with the risk that some samples are misdiagnosed, particularly during the very early stages of disease.
“Recent breakthroughs in nanotechnology have allowed us to manipulate the interaction of light with biological tissue so that abnormal cells appear to have a different colour to healthy ones. Comparing images from our slides to conventional staining is like watching colour television when all you’ve seen before is black and white.”
Associate Professor Parker said current techniques can mean it is difficult to distinguish early forms of breast cancer from benign lesions, particularly when there are not many abnormally-shaped cells in a complex tissue.
The NanoMslide makes such a diagnosis much easier.
“When I first looked at a tissue under the microscope on the NanoMslide, I was incredibly excited,” said Associate Professor Parker, who is also an adjunct associate professor at La Trobe.
“For the first time I saw cancer cells just popping up at me. They were a different colour from the surrounding tissue, and it was very easy to distinguish them from surrounding cells.”
Associate Professor Parker believes the NanoMslide will complement existing stains currently in use, to allow for more consistent cancer diagnoses.
“Based on our preliminary findings with the NanoMslide, we think this platform could be really useful in early breast cancer diagnosis, but also in other cancers where we’re really just trying to pick up a few cancer cells in a complex tissue or a blood sample.”
The study was conducted in collaboration with Professor Sandra O’Toole from the Garvan Institute of Medical Research who was the lead pathologist, and clinical and research partners at the Royal Melbourne Hospital, the Olivia Newton‐John Cancer Research Institute, The University of Melbourne and the Australian National University.
Professor Abbey’s group were able to develop their slide technology by harnessing open access equipment and expertise made available by the Melbourne Centre for Nanofabrication, the flagship facility of the Victorian node of the Australian National Fabrication Facility (ANFF-VIC).
This story was originally published on the Peter Mac website. ACRF has backed $9 million of brilliant research at Peter Mac.
Related Posts
